Please join the AAAS Neuropolicy Affinity Group next week, as we continue our series of discussions for 2015,

We are excited to welcome Matthew Bailey, the Executive Vice President for the National Association for Biomedical Research, as he discusses:

“The Animal Rights Impact on Science”

When: Tuesday, June 30th, 2015. 6pm socializing, discussion starts at 6:30pm

Where: AAAS Headquarters, 2nd Floor 1200 New York Ave, NW  (Entrance on 12 & H st)
Room: Revelle

RSVP: here

Questions: AAASneuropolicy@gmail.com

Bio: Mr. Bailey is the Executive Vice President of the National Association for Biomedical Research (NABR).  As a government relations professional focused heavily on science and technology issues, his Washington career has spanned more than 18 years. In 1996, he was a Presidential appointee in the Clinton Administration serving as a Congressional Liaison for the U.S. Secretary of Commerce, and he later went on to handle Congressional Affairs for the National Institute for Standards and Technology (NIST).  At Commerce, Bailey worked closely with leaders from industry, federal labs, universities and governments on issues impacting technology creators and users including innovation policy, broadband, biotechnology, tech-led economic growth, technology transfer, nanotechnology and workforce policy.  On Capitol Hill, his bi-partisan experience includes time as both a legislative aide for Senator Dale Bumpers (D-AR) and as a Congressional Fellow for Representative Connie Morella (R-MD) where he managed issues coming before the House Committee on Science.  Mr. Bailey holds a degree in Political Science and Legal Studies from the University of Arkansas at Little Rock.  As NABR’s then-Director of Government Affairs, he played an instrumental role in the bi-partisan passage of the federal Animal Enterprise Terrorism Act (18 U.S.C. 43), signed by President Bush in 2006.  Currently, he advises university and corporate member institutions on crisis management issues related to animal rights targeting and educates public policy makers in Washington on the critical value of biomedical research.